Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Longeveron Inc. (NASDAQ: LGVN) SEC filings, giving investors a primary source of regulatory information about the clinical stage biotechnology company and its cellular therapy programs. Longeveron files a range of documents with the U.S. Securities and Exchange Commission, including Forms 8-K, registration statements, and other reports that describe its business, capital structure, and material events.
Recent 8-K filings have detailed topics such as public offerings of Class A common stock and warrants, an at-the-market (ATM) offering agreement, financial results for quarterly periods, changes in executive leadership and board composition, and a Nasdaq notice regarding the minimum bid price requirement for continued listing on The Nasdaq Capital Market. These filings also discuss how the company intends to use offering proceeds, including funding clinical and regulatory development of its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B), for indications like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Through registration statements on Form S-1 and related amendments, Longeveron outlines the terms of securities offerings, its status as an emerging growth and smaller reporting company, and risk factors associated with its business and development plans. Investors can also review disclosures about ATM programs and material definitive agreements with placement agents.
On Stock Titan, these LGVN SEC filings are paired with AI-powered summaries that highlight key points, such as financing terms, listing compliance updates, and planned uses of capital. Users can quickly locate quarterly and annual reporting documents, transaction-related filings, and other regulatory disclosures to better understand Longeveron’s operations, funding strategy, and clinical development priorities.
Longeveron Inc. General Counsel and Secretary Paul T. Lehr reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 5,611 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations.
Following this tax-withholding event, Lehr directly holds 338,566 shares of Class A common stock, which the disclosure notes includes restricted stock units that are subject to future vesting.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 13,145 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations, rather than sold in the open market.
After this withholding, she directly holds 203,419 shares of Class A common stock, which includes RSUs that are still subject to future vesting. The filing reflects compensation-related share vesting mechanics, not an active decision to buy or sell shares.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported a routine tax-related share disposition. On April 1, 2026, 13,145 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations tied to vesting of a restricted stock unit award.
After this withholding, Locklear directly holds 215,686 shares of Class A Common Stock, which the disclosure states includes RSUs that are still subject to future vesting. The filing does not show any open-market buying or selling activity.
Longeveron Inc. Chief Executive Officer Willard Stephen H reported a routine tax-related share transaction. On the vesting of a restricted stock unit (RSU) award, 4,740 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations, rather than being sold in the open market.
Following this tax-withholding disposition, he directly holds 289,727 shares of Class A Common Stock, which includes RSUs subject to future vesting.
Longeveron Inc. executive Devin Blass, CTO & SVP of CMC, reported a routine share disposition related to taxes rather than an open-market trade. On the vesting of a restricted stock unit award, 8,633 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations. After this tax-withholding event, Blass directly holds 191,543 shares of Class A Common Stock, including RSUs that remain subject to future vesting.
Longeveron Inc. received an additional 180-day period from Nasdaq, until September 21, 2026, to regain compliance with the $1.00 minimum bid price requirement for its Class A common stock. The company remains listed on The Nasdaq Capital Market while it works to restore compliance.
If the closing bid price reaches at least $1.00 per share for ten consecutive business days within this period, Nasdaq can confirm that the requirement has been met. Longeveron plans to monitor its stock price and may use options such as a reverse stock split, but there is no assurance it will satisfy Nasdaq’s listing standards.
Longeveron Inc. cancelled its special meeting of stockholders that had been scheduled for 2026. The company now intends for the previously planned Reverse Stock Split proposal from its March 3, 2026 preliminary proxy statement to be presented instead at its next regularly scheduled annual meeting if it determines this is necessary or advisable.
The filing also includes standard cautionary language that forward-looking statements are subject to risks and uncertainties described in Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC reports, and notes the company has no obligation to update such statements except as required by law.
Longeveron Inc. is a clinical-stage biotech focused on regenerative cell therapies built around its lead product, laromestrocel (Lomecel‑B), an allogeneic bone‑marrow–derived mesenchymal stem cell therapy. The company is developing laromestrocel for four indications: Hypoplastic Left Heart Syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging‑related frailty.
For HLHS, laromestrocel has Rare Pediatric Disease, Orphan Drug, and Fast Track designations, and the pivotal Phase 2b ELPIS II trial is fully enrolled with top‑line data expected in the third quarter of 2026. For mild Alzheimer’s, a Phase 2a trial (CLEAR MIND) showed a favorable safety profile and signals of efficacy, leading to RMAT and Fast Track designations and FDA alignment on a planned pivotal seamless Phase 2/3 design, with the possibility of a BLA based on positive interim data.
The company operates a cGMP facility in Miami for early‑phase supply but plans to use a contract development and manufacturing organization for potential commercial production, and it has built an extensive global patent and trademark portfolio around laromestrocel and its manufacturing and potency assays.
Longeveron Inc. reported that Chief Executive Officer Willard Stephen H received several equity awards. He was granted a stock option for 200,000 shares of Class A common stock at an exercise price of $0.545 per share, vesting quarterly over four years beginning on April 1, 2026.
He also received an initial hire award of 200,000 shares of Class A common stock, with 105,533 of those shares withheld to cover tax obligations. In addition, he was granted 200,000 time-based vesting RSUs. Following these awards and tax withholding, he directly holds 294,467 shares of Class A common stock, which includes RSUs subject to future vesting.
Longeveron Inc. Chief Executive Officer Willard Stephen H filed an initial ownership report on Class A Common Stock. The Form 3 shows he beneficially owns no securities, with total Class A Common Stock reported as zero. A footnote explicitly states that no securities are beneficially owned, establishing a baseline of zero ownership for future insider filings.